This page shows the latest Huntingdon's disease news and features for those working in and with pharma, biotech and healthcare.
More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’ status by the European Medicines Agency (EMA). ... s disease to regulatory approval faster.
Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure’s candidate fit the bill, not least because there are no currently approved
Antibody development agreement is worth up to $600m. Roche has upped its efforts in Parkinson's disease by agreeing to research new antibodies with the US biotech Prothena. ... This technology was also a key aspect of a recent deal with Isis to tackle
The unmet medical need for Huntingdon's disease is compounded by its severity, with patients enduring progressive loss of both mental faculties and physical control. ... foundation exclusively dedicated to the development of therapies that slow the
The deal should speed up new treatments for Huntingdon's disease, Parkinson's disease and for strokes. ... attention to incidents of vision loss among patients taking GSK's Levitra, Pfizer's Viagra and Lilly's Cialis.
The market for ReNeuron's treatment is large with some 12m stroke survivors in Japan, the US and the EU, with nearly one third needing continual nursing care. ... ReNeuron is also focusing on inherited Huntingdon's disease and type 1 diabetes needing
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...